Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Timothy R. Donahue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1175-2545; OpenAlex author ID A5058851560; NIH RePORTER profile ID 10343914. Sources: OpenAlex.

Their work

Papers
64 (first author 2, last author 22)
Trials
0
Grants
5
Labs led
1
Collaborators
193
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 3 papers · 2014: 5 papers · 2015: 6 papers · 2016: 8 papers · 2017: 2 papers · 2018: 3 papers, 1 grant · 2019: 4 papers, 1 grant · 2020: 3 papers · 2021: 4 papers · 2022: 4 papers · 2023: 3 papers · 2024: 8 papers · 2025: 1 paper, 2 grants · 2026: 6 papers, 1 grant

Papers 50 of 64

  1. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Last author DOI 10.1016/j.gassur.2026.102358↗
  2. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Last author DOI 10.1038/s41467-026-68976-2↗
  3. A Computer Vision Algorithm to Predict Superior Mesenteric Artery Margin Status for Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006506↗
  4. Improved Survival with Delayed Surgery at High-Volume Centers Versus Early Surgery at Low-Volume Centers for Pancreatic Cancer. Last author DOI 10.1245/s10434-025-19052-4↗
  5. ASO Visual Abstract: Improved Survival with Delayed Surgery at High-Volume Centers versus Early Surgery at Low-Volume Centers for Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19232-w↗
  6. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  7. Inhibition of AXL dependent non-professional efferocytosis sensitizes pancreatic cancer to immune checkpoint blockade Co-author DOI 10.1101/2025.08.12.669943↗
  8. Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resec… Co-author DOI 10.1002/jso.27674↗
  9. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27695↗
  10. Disparities in neoadjuvant chemotherapy for pancreatic adenocarcinoma with vascular involvement. Last author DOI 10.1016/j.sopen.2024.06.003↗
  11. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Last author DOI 10.1016/j.surg.2024.01.008↗
  12. Carnitine palmitoyltransferase 1B mediates gemcitabine resistance in pancreatic cancer. First author DOI 10.1016/j.surg.2024.02.018↗
  13. Center-level variation in hospitalization costs of pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.1016/j.surg.2024.05.038↗
  14. Association of Inpatient Palliative Care Consultation with Clinical and Financial Outcomes for Pancreatic Cancer. Last author DOI 10.1245/s10434-023-14528-7↗
  15. ASO Author Reflections: Unlocking the Value of Inpatient Palliative Care for Patients with Pancreatic Cancer. Last author DOI 10.1245/s10434-023-14622-w↗
  16. MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling. Last author DOI 10.1158/1078-0432.ccr-22-3322↗
  17. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1066↗
  18. Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-10658-z↗
  19. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Co-author DOI 10.1016/j.celrep.2021.110236↗
  20. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Last author DOI 10.1016/j.surg.2021.10.015↗
  21. Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0623↗
  22. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2967/jnumed.121.261952↗
  23. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Co-author DOI 10.1002/jso.26279↗
  24. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  25. NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Last author DOI 10.1073/pnas.2012469118↗
  26. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  27. The Utility of EUS-FNA to Determine Surgical Candidacy in Patients with Pancreatic Cancer after Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-019-04415-6↗
  28. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Last author DOI 10.1016/j.surg.2019.12.008↗
  29. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment. Co-author DOI 10.1038/s41467-020-17996-7↗
  30. Pancreatic Cancer. First author DOI 10.1001/jama.2019.14699↗
  31. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  32. Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Last author DOI 10.1073/pnas.1812410116↗
  33. Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001349↗
  34. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retro… Co-author DOI 10.1007/s11523-018-0572-3↗
  35. A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer. Last author DOI 10.1007/s11605-017-3607-7↗
  36. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. Co-author DOI 10.2967/jnumed.117.207332↗
  37. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. Co-author DOI 10.1172/jci92284↗
  38. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Last author DOI 10.18632/oncotarget.13572↗
  39. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. Last author DOI 10.1007/s11605-016-3149-4↗
  40. Long-term survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2015.12.024↗
  41. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. Co-author DOI 10.1016/j.tem.2016.06.009↗
  42. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. Co-author DOI 10.1021/acsnano.5b07781↗
  43. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
  44. Stiffness of pancreatic cancer cells is associated with increased invasive potential. Co-author DOI 10.1039/c6ib00135a↗
  45. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Co-author DOI 10.1152/ajpgi.00035.2016↗
  46. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-15-0774↗
  47. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. Last author DOI 10.1002/jso.24011↗
  48. Plastic biliary stent patency in patients with locally advanced pancreatic adenocarcinoma receiving downstaging chemotherapy. Co-author DOI 10.1016/j.gie.2014.08.020↗
  49. p85α is a microRNA target and affects chemosensitivity in pancreatic cancer. Last author DOI 10.1016/j.jss.2015.02.071↗
  50. Surgical management of pancreatic cancer--pancreaticoduodenectomy. Co-author DOI 10.1053/j.seminoncol.2014.12.009↗

Grants 5

  1. Causes and Consequences of Adenosine Signaling in Pancreatic Cancer R01CA290888↗
  2. Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer R01CA250529↗
  3. Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer R01CA260678↗
  4. UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer U01CA198846↗
  5. PET Imaging-guided Personalized Therapy in Pancreatic Cancer R01CA187678↗

Closest collaborators

The 25 strongest of 193 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caius Gabriel Radu · 8 shared papers, 4 shared grants, 2017–2026 · strength 4.17
  2. Zev A. Wainberg · 12 shared papers, 2 shared grants, 2013–2026 · strength 3.21
  3. Mark D. Girgis · 11 shared papers, 2016–2026 · strength 1.71
  4. David W. Dawson · 21 shared papers, 2011–2026 · strength 1.71
  5. Oscar Joe Hines · 13 shared papers, 2013–2026 · strength 1.24
  6. Sara Sakowitz · 3 shared papers, 2024–2026 · strength 1.09
  7. Joon Y. Park · 6 shared papers, 2021–2025 · strength 1.07
  8. Nikhil L. Chervu · 5 shared papers, 2024 · strength 1.07
  9. Shineui Kim · 4 shared papers, 2024–2026 · strength 0.89
  10. Jason M. Link · 5 shared papers, 2022–2026 · strength 0.86
  11. Howard A. Reber · 12 shared papers, 2011–2021 · strength 0.83
  12. Jonathan C. King · 4 shared papers, 2021–2026 · strength 0.79
  13. Michael K. Srienc · 2 shared papers, 2024–2026 · strength 0.66
  14. Evan R. Abt · 5 shared papers, 2019–2026 · strength 0.64
  15. Shimpei Maeda · 4 shared papers, 2020–2026 · strength 0.60
  16. Alexandra M. Moore · 5 shared papers, 2019–2022 · strength 0.58
  17. Johannes Czernin · 2 shared papers, 1 shared grant, 2018–2022 · strength 0.53
  18. Keith D. Lillemoe · 3 shared papers, 2022–2026 · strength 0.51
  19. Huan Meng · 3 shared papers, 1 shared grant, 2016–2020 · strength 0.51
  20. Amol Kumar Narang · 3 shared papers, 2021–2026 · strength 0.50
  21. Michael A. Mederos · 3 shared papers, 2021–2024 · strength 0.47
  22. Neema Jamshidi · 2 shared papers, 2023–2026 · strength 0.47
  23. Nguyen Le · 2 shared papers, 2024 · strength 0.45
  24. Andrew M. Lowy · 4 shared papers, 2019–2026 · strength 0.42
  25. André E. Nel · 2 shared papers, 1 shared grant, 2016–2019 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.